Cargando…

Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis

INTRODUCTION: Patients with psoriatic arthritis (PsA) who receive an initial tumor necrosis factor inhibitor (TNFi) may switch to another TNFi or a non-TNFi biologic therapy. This study compared the healthcare resource use (HRU), expenditures, and time to discontinuation among TNFi-experienced patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Yan, Betts, Keith A., Lu, Yichen, Singh, Rakesh, Clewell, Jerry, Griffith, Jenny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514202/ https://www.ncbi.nlm.nih.gov/pubmed/31055779 http://dx.doi.org/10.1007/s40744-019-0158-2

Ejemplares similares

Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US
por: Strand, Vibeke, et al.
Publicado: (2016)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2020)

Economic impact of biologic utilization patterns in patients with psoriatic arthritis
por: Schwartzman, Sergio, et al.
Publicado: (2017)

Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry
por: Bergman, Martin J., et al.
Publicado: (2022)

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
por: Mease, Philip J, et al.
Publicado: (2019)

Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence
por: Costa, Luisa, et al.
Publicado: (2017)

Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
por: Wu, Jashin J., et al.
Publicado: (2020)

Economic and Comorbidity Burden Among Moderate‐to‐Severe Psoriasis Patients with Comorbid Psoriatic Arthritis
por: Feldman, Steven R., et al.
Publicado: (2015)

Perspectives on Treatment Burden for Methotrexate and Tumor Necrosis Factor Inhibitors Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis: A Qualitative Study
por: Ogdie, Alexis, et al.
Publicado: (2023)

The burden of psoriasis in patients with early psoriatic arthritis
por: Kasiem, Fazira R, et al.
Publicado: (2021)

First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study
por: da Silva, Michael Ruberson Ribeiro, et al.
Publicado: (2022)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
por: Bhushan, Vandana, et al.
Publicado: (2021)

Altered Bone Biology in Psoriatic Arthritis
por: Rahimi, Homaira, et al.
Publicado: (2012)

Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab
por: Chiorean, Michael, et al.
Publicado: (2020)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2020)

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis
por: Valenzuela, Fernando, et al.
Publicado: (2021)

The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy
por: Olivieri, I., et al.
Publicado: (2008)

A Comparison of Disease Burden in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis
por: Michelsen, Brigitte, et al.
Publicado: (2015)

Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Furer, Victoria, et al.
Publicado: (2023)

Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
por: Bergman, Martin, et al.
Publicado: (2021)

Real-world burden of comorbidities in US patients with psoriatic arthritis
por: Shah, Kamal, et al.
Publicado: (2017)

Burden and Disease Characteristics of Psoriatic Arthritis at a Tertiary Center
por: Attar, Suzan, et al.
Publicado: (2022)

Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis
por: Cawson, Matthew Richard, et al.
Publicado: (2014)

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
por: D’Angelo, Salvatore, et al.
Publicado: (2017)

Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis
por: Ogdie, Alexis, et al.
Publicado: (2022)

Prevalence of psoriatic arthritis in Chinese population with psoriasis: A multicenter study conducted by experienced rheumatologists
por: Zhang, Hua, et al.
Publicado: (2023)

Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis
por: Wervers, Kim, et al.
Publicado: (2018)

Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics
por: Silvy, Florent, et al.
Publicado: (2015)

Quo vadis, biological treatment for psoriasis and psoriatic arthritis?
por: Olszewska, Barbara, et al.
Publicado: (2018)

Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis
por: Thibodeaux, Quinn, et al.
Publicado: (2019)

Treatment persistence of biologics among patients with psoriatic arthritis
por: Haddad, Amir, et al.
Publicado: (2021)

Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis
por: Zhang, Hanzhe, et al.
Publicado: (2021)

Psoriatic arthritis
por: Sankowski, Artur Jacek, et al.
Publicado: (2013)

Psoriatic Arthritis
por: Fitzgerald, Kara, et al.
Publicado: (2012)

Psoriatic arthritis
por: Ocampo D, Vanessa, et al.
Publicado: (2019)

Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population
por: Lee, Seina, et al.
Publicado: (2018)

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis
por: Cannon, Grant W., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j6kbtvt03ejg1hdmo8rb1k6nf4